Development and Validation of HPTLC Method for Estimation of Saroglitazar in Bulk and Pharmaceutical Dosage Form

Research Article

Austin J Anal Pharm Chem. 2015;2(2): 1035.

Development and Validation of HPTLC Method for Estimation of Saroglitazar in Bulk and Pharmaceutical Dosage Form

Patel NM*, Mehta FA, Shah DA and Chhalotiya UK

Department of Pharmaceutical chemistry and analysis, Indukaka Ipcowala College Of Pharmacy, India

*Corresponding author: Nikita M Patel, Indukaka Ipcowala College of Pharmacy, India.

Received: March 17, 2015; Accepted: April 07, 2015; Published: April 09, 2015

Abstract

A simple, sensitive, and precise high-performance thin-layer chromatographic method has been developed for the estimation of Saroglitazar (SAR). The method employed was thin-layer chromatography (TLC). Aluminum plates precoated with silica gel 60 F254 were used as the stationary phase, while the solvent system was n-butanol: ammonia (7:3 v/v). The Rf value was observed to be 0.55 ± 0.02. The spot was densitometrically analyzed at 294 nm. The method was linear in the range of 125-1500 ng/ band. The limit of detection for SAR was found to be 13.09 ng/ band. The limit of quantification for SAR was found to be 39.68 ng /band. The proposed method was validated with respect to linearity, accuracy, precision and robustness. The method was successfully applied to the estimation of SAR in formulation.

Keywords: HPTLC; Saroglitazar; Validation

Introduction

Saroglitazar (SAR) is chemically(S)-a-ethoxy-4-[2-[2-methyl-5- [4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethoxy] benzenepropanoic acid magnesium salt (2:1) has the empirical formula [C25H28NO4S]2Mg with molecular weight 900 (g/ mol) (Figure 1) [1]. Peroxisome proliferator activated receptor (PPAR) α and γ agonists are approved hypolipidemic and anti-diabetic agents respectively and combining them together provides a dual benefit in type 2 diabetes mellitus associated with dyslipidemia. This novel class of dual PPAR agonists is termed as “Glitazars” [2]. SAR is the first glitazar class compound that has been approved as a therapeutic agent [1]. Other compounds of the same chemical class such as Rapaglitazar, Cipoglitazar, Aleglitazar etc. are failed in the clinical trials. SAR is a dual regulator that corrects both the lipid profile and the glycemic indices [3]. SAR is indicated for the treatment of dyslipidemia and has favourable effects on glycaemic parameters in type 2 diabetes mellitus [4]. Structurally, SAR is a non-TZD and non-fibrate molecule and belongs to aryl alkoxy propionic acid class. SAR is a dual PPAR (peroxisome proliferator activated receptor) -α/γ agonist having strong PPAR-α effect with moderate PPAR-γ effect. Agonist action at PPAR-α lowers high blood triglycerides and agonist action on PPAR-γ improves insulin resistance and consequently lowers blood sugar [5]. SAR is indicated for the treatment of diabetic dyslipidemia or hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy [6].